Drug Trial Radar · NCT02854072
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
Last checked: Nov 19, 2026Latest source record: Nov 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
148
Planned (sponsor's estimate)
Start
Nov 2015
Primary completion
May 2018
Study completion May 2018
Sponsor
- Lead sponsor
- Samsung Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess treatment of GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in locally advanced and metastatic pancreatic cancer patients.
Conditions
- Pancreatic Cancer
Interventions
GV1001Drug
At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
GemcitabineDrug
Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
CapecitabineDrug
Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: one year
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Pusan National University Hospital
Busan, South Korea · Recruiting
Daegu Catholic University Medical Center
Daegu, South Korea · Recruiting
Konyang University Hospital
Daejeon, South Korea · Recruiting
Chonnam National University Hospital
Gwangju, South Korea · Recruiting
Gachon University Gil Medical Center
Incheon, South Korea · Recruiting
Gangnam Severance Hospital
Seoul, South Korea · Recruiting
Hanyang University Seoul Hospital
Seoul, South Korea · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea · Recruiting
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea · Recruiting
Jeju National University Hospital
Jeju City, Jeju-do, South Korea · Recruiting
Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea · Recruiting
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.